following sequence of reactions to these grafts. Host function of this molecule is the elimination of Fas-expressing infiltrating leukocytes. On the other hand, we alloreactive T cells enter the graft, recognize alloantigens on testicular tissue, and are activated. As a result, cannot rule out the possibility that the Fas-FasL pathway also serves some as-yet-unknown nonimmunologic the T cells begin to express Fas and become targets for the cytolytic action of FasL, which is normally and function in the testes and eyes. Immunological Tolerance: Preventing Immune constitutively expressed on Sertoli cells in the testis ( Figure 1A ). This leads to the unusual situation of the Reactions against Self-Antigens There are several theoretical and mechanistic parallels graft "rejecting" (killing) host cells and thus protecting itself. Sertoli cells may function as immunological guardbetween immune privilege and immunological tolerance. In both situations, the underlying mechanism is ians to block the development of all immune reactions in the testis and not just transplant rejection. To establish the inactivation or elimination (or both) of antigen-responsive lymphocytes. Immune privilege, as discussed formally the role of the Fas-FasL pathway in immune privilege, it will be necessary to show that diverse foreign above, is maintained in some tissues because of the ability of these tissues to destroy infiltrating lymphoprotein antigens (including tissue grafts) placed in the testes of normal mice will not elicit specific immune cytes. Immunological tolerance is maintained in part by the ability of lymphocytes to kill themselves or one responses, whereas the same antigens introduced into the testes of Fas-deficient lpr/lpr mice or FasL-mutant another. In fact, the situation in which the protective value of Fas-FasL interactions was first described was gld/gld mice will stimulate such responses. The testicular transplant experiments done to date suggest that the prevention of autoimmunity. The seminal observations that established this idea were the demonstration this hypothesis will prove to be correct.
A second study has more directly evaluated the role that in two mouse models of systemic autoimmunity, lpr and gld homozygous mice, the key abnormalities of Fas-FasL interactions in preventing local immune reactions, this time in the eye. Griffith et al. (1995) have were defective expression of Fas or a mutation in FasL, respectively (Nagata and Suda, 1995) . Abnormalities in shown that if herpes simplex virus is introduced into the anterior chamber of the eyes of normal mice, it elicits Fas are also known to cause systemic autoimmune diseases in humans (Rieux-Laucaut et al., 1995; Fisher et a mild, local inflammatory response, with detectable apoptosis of infiltrating leukocytes. In contrast, the same al., 1995). Such abnormalities include inheritance of two mutant alleles, undefined signaling defects, and inheriviral infection in Fas-deficient lpr/lpr mice or FasL-mutant gld/gld mice leads to a more severe inflammation tance of dominant negative mutants. An intriguing observation is that some children who inherit dominant that spreads to the posterior chamber. FasL is expressed on the corneal epithelium, iris, and retina in the negative mutants show defects in Fas-mediated apoptosis and develop autoimmune disease, whereas eye and presumably functions to kill any leukocytes that enter in response to the local viral infection and that the parents who carry the mutant genes also show apoptosis defects but are clinically unaffected (Fisher et express Fas. This is supported by the finding that, in vitro, explants of the cornea and iris from normal eyes, al., 1995) . This raises the possibility that the phenotypic manifestations of disease may be influenced by modibut not eyes of gld/gld mice, are capable of inducing apoptosis of Fas-expressing targets. In the case of the fying factors, which have not been identified yet. The mechanism by which Fas-FasL interactions mainocular infection, immune privilege is, of course, not advantageous to the host, because it allows the infection tain immunological tolerance to self-antigens has been inferred from a variety of studies. It is thought that if to proceed unchecked.
Fas-dependent leukocyte elimination may not be the CD4 ϩ helper T lymphocytes are repeatedly stimulated by their cognate antigen, these T cells express high only mechanism for preventing inflammatory immune responses in the eye. In several experimental studies, levels of Fas and FasL and kill either themselves or one another ( Figure 1B ). Such a homeostatic mechanism it has been shown that antigens introduced into the anterior chamber do elicit immune responses, but such may limit the size of lymphocyte clones responding to foreign antigens. The same mechanism may be trigresponses tend to be suppressive: that is, they inhibit potentially injurious, inflammatory immune reactions at gered by abundant and disseminated self-antigens, which are able to interact repeatedly with specific T both local and distant sites (Ksander and Streilein, 1994) . In these situations, immune privilege is not due to a cells. The available evidence indicates that Fas plays little or no role in selecting developing T cells in thymus failure of immune responses. Rather, antigens introduced into the eye may induce a form of "immune deviaand that abnormalities in Fas are manifested by a defect in antigen-induced deletion of mature T cells in periphtion" in which anti-inflammatory immune reactions predominate. Whether or not FasL-mediated cell death eral lymphoid tissues (Singer and Abbas, 1994) . Thus, in lpr and gld homozygous mice, autoimmunity is associplays a role in biasing immune responses toward the anti-inflammatory route is an open question.
ated with a failure of deletion of mature T cells and is not due to abnormal lymphocyte maturation or selection Two other issues relevant to immune privilege are worth mentioning. First, there is, as yet, no evidence of the repertoire of mature lymphocytes. These findings also emphasize the importance of peripheral tolerance that the CNS also constitutively expresses FasL. In fact, immune privilege in the CNS may be due to anatomic in maintaining unresponsiveness to self-antigens. In addition to its role in T cell deletion, Fas is also involved factors, such as the exclusion of lymphocytes by the normal blood-brain barrier. Second, it is intriguing that in the elimination of unwanted B lymphocytes. Thus, B cells that encounter self-antigens may express Fas, may the eye and the testis are the only tissues that constitutively express FasL. It may be that the only physiologic remain sensitive to killing by FasL expressed on helper IL-2 receptor is multisystem autoimmune disease. In the Singer, G.G., and Abbas, A.K. (1994 T cells (Willerford et al., 1995) .
Prospects for Therapy
These studies on the physiologic functions of Fas and FasL have raised the exciting possibility that this pathway can be exploited in a beneficial way. For instance, it may be feasible to endow allografts or xenografts with the property of immune privilege, or resistance to rejection, by expressing FasL in the donor tissues. Obviously, it will be necessary to show that the tissue in which FasL is to be expressed does not also express Fas so that it does not injure itself. Attempts to express FasL as a transgene in the ␤ cells of the islets of Langerhans of mice and to use these FasL ϩ cells as grafts for treating diabetes are already underway. In theory, the same approach may be useful for developing universal islet xenografts. However, a major barrier to xenotransplantation is antibody-mediated hyperacute rejection, and this will obviously not be prevented by FasL. In the long term, one can envision donor tissues expressing multiple human genes designed to prevent different humoral and cellular mechanisms of graft rejection.
The Fas-FasL pathway may also be exploited for treating autoimmune diseases. One example of this is a study in which mice were immunized with a myelin antigen so that they developed encephalomyelitis. Repeated administration of the same antigen led to elimination of specific T cells, presumably by Fas-mediated apoptosis, and to amelioration of disease (Critchfield et al., 1994) . The danger in such a therapeutic protocol is obvious, since it relies on activating potentially dangerous T cells prior to inducing the death of these cells. Nevertheless, controlled administration of self-antigens or pharmacologic induction of cell death in autoreactive lymphocytes may prove to be valuable in the treatment of autoimmune diseases.
